Defined Bacterial Strain Composition for NAFLD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic fatty liver disease (NAFLD) such as fecal microbial transplantation (FMT) are poorly characterized, pose transmission risks, and have significant side effects, lacking a long-term therapeutic option for chronic conditions like NASH.
Innovation Solution
A composition comprising specific bacterial strains from the genera Faecalibacterium, Butyricicoccus, Roseburia, Akkermansia, Lactiplantibacillus, and Anaerostipes, capable of producing butyrate and propionate, is used to treat, delay, or prevent liver diseases and conditions, including NAFLD, NASH, liver fibrosis, and hepatocellular carcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fecal microbial transplantation (FMT) is used to treat NAFLD, then microbial composition may be improved, but transmission risks of infectious diseases increase and the procedure is poorly characterized
Solution Approach 1:
The patent extracts and isolates specific beneficial bacterial strains (Faecalibacterium prausnitzii, Butyricicoccus pullicaecorum, Roseburia inulinivorans, Roseburia hominis, Akkermansia muciniphila, Lactobacillus plantarum, and Anaerostipes caccae) from fecal matter, separating them from the potentially harmful components of raw fecal transplants. This extraction approach maintains therapeutic benefits while eliminating transmission risks associated with whole fecal matter transplantation.
Solution Approach 2:
The patent segments the complex fecal microbial community into discrete, characterized bacterial strains with known safety profiles. Each strain is isolated and characterized individually, allowing for controlled administration and eliminating the unpredictability and safety concerns associated with uncharacterized fecal matter transplantation.
2Reliability
If lipid modulators such as thiazolidinediones (TZDs) are used to treat NAFLD, then insulin resistance and hyperlipidemia are improved, but weight gain, fluid retention and risk of myocardial infarction increase
Solution Approach 1:
The patent introduces probiotic bacterial strains as intermediary agents that produce short-chain fatty acids (butyrate, propionate) which indirectly improve metabolic parameters. These bacteria act as mediators that enhance insulin sensitivity and lipid metabolism through microbial metabolites rather than direct pharmacological action, avoiding the harmful side effects of TZDs while achieving similar metabolic improvements.
3Ease of operation
If NASH is treated with conventional therapies, then some symptoms are managed, but no approved pharmacotherapy exists and the disease progresses to fibrosis, cirrhosis, and hepatocellular carcinoma
Solution Approach 1:
The patent applies preliminary action by administering probiotic bacteria that prevent disease progression before NASH advances to fibrosis and cirrhosis. The beneficial strains work preemptively to reduce inflammation, improve insulin sensitivity, and prevent the metabolic dysregulation that drives progression to more severe liver disease stages, offering long-term therapeutic benefit rather than just symptom management.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bacterial strain composition reduces weight gain, insulin levels, insulin resistance, liver inflammation, steatosis, and fibrosis, providing a safer and more effective long-term therapeutic option for NAFLD and associated conditions.
Implementation Method 1
a composition comprising two or more bacterial strains of at least two of the following genera: Faecalibacterium, butyricicoccus, roseburia, akkermansia, lactiplantibacillus and anaerostipes... capable of producing butyrate and propionate
Data Source
AI summary
Described herein is a composition comprising two or more bacterial strains belonging to at least two of the following genera: Faecalibacterium, Butyricicoccus, Roseburia, Akkermansia, Lactiplantibacillus or Anaerostipes. Aspects described herein may be used in the treatment of a disease or condition of the liver, a symptom thereof.